TAK-755 (rADAMTS13)
Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Phase 3Active
Key Facts
Indication
Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Phase
Phase 3
Status
Active
Company
About Takeda Pharmaceutical
Takeda Pharmaceutical is a purpose-driven, global biopharmaceutical leader with a mission to create better health for people and a brighter future for the world. Its strategy is built on a balanced, diverse portfolio across five core therapeutic areas and a commitment to translating advanced science into life-transforming treatments. The company's 2019 acquisition of Shire plc was a pivotal event, establishing its leadership in rare diseases and significantly expanding its global footprint. Takeda is now executing a transformation to strengthen competitiveness and accelerate future growth, focusing on innovation, operational excellence, and sustainability.
View full company profile